RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the expansion of the phase 2 clinical program for the novel antifungal agent VT-1161. The initial phase 2 study previously announced is designed to evaluate the safety and efficacy of VT-1161 in the oral treatment of acute vulvovaginal candidiasis (VVC). A second phase 2 clinical study has been initiated to evaluate the safety and efficacy of VT-1161 in the oral treatment of moderate to severe interdigital tinea pedis, commonly called athlete’s foot. Both studies are being conducted at leading clinical centers in the United States. VT-1161 has been shown in preclinical studies to potently inhibit, in a safe and selective manner, a wide range of fungal pathogens causing human disease. In previous phase 1 clinical studies, VT-1161 demonstrated good safety, tolerability and pharmacokinetics.
Help employers find you! Check out all the jobs and post your resume.
